Equities analysts expect SAGE Therapeutics Inc (NASDAQ:SAGE) to report ($2.39) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for SAGE Therapeutics’ earnings, with the highest EPS estimate coming in at ($2.02) and the lowest estimate coming in at ($2.79). SAGE Therapeutics posted earnings per share of ($1.97) during the same quarter last year, which would indicate a negative year-over-year growth rate of 21.3%. The business is expected to announce its next earnings results on Thursday, November 1st.

According to Zacks, analysts expect that SAGE Therapeutics will report full year earnings of ($7.99) per share for the current fiscal year, with EPS estimates ranging from ($10.62) to ($6.23). For the next financial year, analysts forecast that the business will post earnings of ($10.47) per share, with EPS estimates ranging from ($21.68) to ($5.06). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover SAGE Therapeutics.

SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.84) by $1.48. The firm had revenue of $90.00 million during the quarter.

Several research analysts have commented on the company. Canaccord Genuity set a $220.00 price objective on SAGE Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 8th. Stifel Nicolaus raised their price objective on SAGE Therapeutics from $198.00 to $239.00 and gave the company a “buy” rating in a research report on Tuesday, August 7th. Piper Jaffray Companies initiated coverage on SAGE Therapeutics in a research report on Monday, August 6th. They set an “overweight” rating and a $206.00 target price on the stock. BidaskClub lowered SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 27th. Finally, Morgan Stanley lifted their target price on SAGE Therapeutics from $225.00 to $228.00 and gave the stock an “overweight” rating in a research report on Friday, July 13th. Two investment analysts have rated the stock with a sell rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $199.19.

NASDAQ:SAGE opened at $149.74 on Tuesday. SAGE Therapeutics has a 12 month low of $59.57 and a 12 month high of $195.97. The stock has a market capitalization of $6.92 billion, a price-to-earnings ratio of -21.12 and a beta of 2.88.

A number of institutional investors have recently made changes to their positions in the stock. FMR LLC increased its holdings in SAGE Therapeutics by 1.6% in the second quarter. FMR LLC now owns 6,977,378 shares of the biopharmaceutical company’s stock valued at $1,092,169,000 after buying an additional 110,687 shares during the last quarter. BlackRock Inc. increased its holdings in SAGE Therapeutics by 9.6% in the first quarter. BlackRock Inc. now owns 3,774,283 shares of the biopharmaceutical company’s stock valued at $607,923,000 after buying an additional 330,112 shares during the last quarter. OppenheimerFunds Inc. increased its holdings in SAGE Therapeutics by 2.2% in the second quarter. OppenheimerFunds Inc. now owns 1,598,167 shares of the biopharmaceutical company’s stock valued at $250,162,000 after buying an additional 34,389 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in SAGE Therapeutics by 7.6% in the second quarter. Bank of New York Mellon Corp now owns 1,564,548 shares of the biopharmaceutical company’s stock valued at $244,898,000 after buying an additional 110,134 shares during the last quarter. Finally, BB Biotech AG increased its holdings in SAGE Therapeutics by 6.9% in the second quarter. BB Biotech AG now owns 1,071,373 shares of the biopharmaceutical company’s stock valued at $167,702,000 after buying an additional 68,934 shares during the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Recommended Story: Trading Penny Stocks

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.